Hormonal balance is not the end goal. It’s the means.
Women are not waking up thinking, “Today I want balanced follicle-stimulating hormones and luteinizing hormones”. They’re thinking about whether they’ll have the energy to lead a meeting, the clarity to focus, the confidence to show up fully in their relationships – or whether hot flashes, brain fog, irregular cycles, or skin issues will hijack the day.
That gap between biomarker balance and felt experience is where the next generation of women’s health products will win.
Women’s hormonal health is no longer niche. Market data shows that the women’s hormonal health market is valued at $4.5bn, projected to reach a CAGR of 7.6% through 2032. Additionally, women are willing to spend 25% more on products specific to perimenopause and menopause.
From ancient herb to modern benchmark
Shatavari (Asparagus racemosus) has been used for more than 3,500 years in Ayurvedic medicine as the “Queen of Herbs” for women. Shatavari is a perennial herb native to the Indian subcontinent and has been a cornerstone of traditional Ayurvedic medicine for thousands of years.
The name shatavari translates to “she who has 100 husbands”, reflecting its use to promote vitality in women. Shatavari has traditionally occupied a central role in the health of women, and it was used to improve fertility, support reproductive health, and promote lactation, as well as aid digestion, bolster immunity, and provide adaptogenic support. Shatavari is still widely used in Ayurvedic medicine, but tradition alone doesn’t move today’s market.
By integrating modern technology with centuries of ethnomedicinal knowledge, Xeya Modern Shatavari by NTX USA translates and builds on invaluable experience to make a solution compatible with present-day lifestyles. Two areas were especially key to this transformation: modern extraction methods along with robust clinical validation of health benefits.
Why dose is the new differentiator
Xeya Modern Shatavari represents a modern reengineering of this classic botanical. It contains high levels of bioactive compounds that are efficiently captured using advanced extraction technologies.
The result is a highly potent material. Xeya Modern Shatavari is standardized to 15% shatavarins, while commodity commercial extracts typically sit at 5% to 6%, and some on the market claim as high as 7% or even as much as 10%. That high standardization level of bioactive phytochemicals in Xeya Modern Shatavari translates to lower dose – and clinical validation in multiple human studies using doses of either 50mg or 100mg proves its value at that low dose.
Most shatavari ingredients on the market require 300mg to 500mg per serving. Xeya Modern Shatavari delivers comparable – or superior – outcomes at as little as one-fifth of the dose. For formulators, that changes everything.
Lower dose means:
- More room in the capsule for synergistic ingredients
- Smaller, more consumer-friendly formats like gummies
- Lower cost-in-use
- Cleaner, more focused claims architecture
Two life stages, one adaptogenic solution
What truly sets Xeya Modern Shatavari apart is not just what it does but how it does it. Because of two clinical trials on two different study populations – with different results on hormone levels – Xeya can rightfully be described as a hormonal adaptogen.
This is illustrated in its effects on three biomarkers that were measured in two published clinical studies.
In a 2025 study, women with Polycystic Ovary Syndrome, or PCOS (ages 20 to 35), hormones like LH and androgens tend to run high. In another 2025 study (detailed in NutraIngredients), perimenopausal women (ages 40 to 49) saw estrogen and progesterone decline while follicle-stimulating hormone (FSH) and luteinizing hormone (LH) rose erratically.1
If an ingredient simply pushes hormones up or down, it risks helping one group while harming another.
Instead, the 15% shatavarin material moves the outcomes in opposite directions, bringing the body back to balance. Shatavari is not often described in terms of being a hormonal adaptogen because clinical trials using the same material on different populations have not been published. Yet this is exactly what Xeya Modern Shatavari has been shown to do, based on the results of the two 2025 published human clinical trials.
Clinical evidence: PCOS
In the 2025 clinical study on women with PCOS, Xeya Modern Shatavari supplementation led to these significant effects:1
- Hormonal balance: 33.9% reduction in total testosterone, 31.8% increase in sex hormone-binding globulin, 18.6% improvement in the ratio of luteinizing hormone to follicle-stimulating hormone (used to assess ovarian function, fertility, and help diagnose conditions like PCOS).
- Supported healthier ovarian morphology, including a 21% reduction in ovarian volume and a 25% reduction in follicle count.
- Significantly improved menstrual cycle regularity, supporting reproductive rhythm.
- Delivered visible improvements in PCOS-associated symptoms, including a 44% reduction in acne severity and a 46% reduction in unwanted hair growth.
- Supported metabolic balance by improving insulin sensitivity, a key driver of hormonal imbalance in PCOS.
Results showed that Xeya Modern Shatavari supports reproductive rhythm, not aggressive hormonal manipulation.
Clinical evidence: Perimenopause
In a randomized, double-blind, placebo-controlled trial published in 2025, women aged 40 to 50 taking 100mg of Xeya Modern Shatavari experienced statistically significant improvements across a wide range of menopausal symptoms – including hot flashes, menstrual discomfort, and overall quality of life, including:2
- Hot flash frequency and intensity dropped 27.6% and 39.8% in the 50mg and 100mg treatment groups, respectively, compared to a 7.7% increase in the placebo group.
- Validated, internationally recognized Menopause Rating Scale (MRS) score of 11 key symptoms significantly decreased by 51.4% and 72.9%, respectively, compared to 22.8% in the placebo group.
- Ovarian follicle count significantly increased, by 34.4% and 51.9%, respectively, compared to no change in the placebo group.
- Dose-dependent modulation observed for four separate hormones, translating to skin and hair quality improvements.
- 74.5% improvement in psychological symptoms, including mood swings, anxiety, and brain fog.
Validated tools like the MRS and Menstrual Symptoms Questionnaire (MSQ) showed meaningful improvements compared to placebo, with line graphs tracking steady symptom reduction across 120 days.
The new shatavari standard
Xeya Modern Shatavari is not just another botanical extract, it’s a clinically validated system supported by:
- Patient-reported outcomes: Validated questionnaires measure women’s experiences, demonstrating real-world symptom relief in mood, sleep, menstrual cycle regularity, and skin/hair quality.
- Physician assessments: Expert clinicians observed visible improvements in ovary function, hormone markers, and menopause symptoms scales.
- Biomarker analysis: Hormonal modulation confirmed through significant movement toward healthier levels of serum estradiol, anti-müllerian hormone (AMH), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and insulin utilization.
- Physical measurements: Symptom improvements women feel and see. Reduced hot flash frequency and intensity, improved skin/acne, sleep quality, mood swings, and cycle regularity.
Together, these form NXT USA’s Four Pillars of Validation™, ensuring claims are not just compelling, but defensible. Strong science builds consumer-resonant claims that sell supplements.
“Women’s concerns have been neglected for too long. This study shows real benefits for women dealing with perimenopausal symptoms, dramatically improving quality of life for the participants,” says Eric Anderson, managing director NXT USA, Metuchen, NJ.
“This is the NXT standard of comprehensive clinical evidence – incorporating our Four Pillars of Validation in study design that measures patient reporting, physician assessment, biomarkers, and physical tests. This is science layered on science.”
Built for modern product development
Beyond efficacy, Xeya Modern Shatavari was developed with real-world formulation in mind. According to formulation data, Xeya is:
- Effective at 50mg to 100mg
- Taste-masked
- Water-dispersible
- Compatible with gummies, capsules, tablets, powders, and functional foods
This versatility allows brands to innovate across formats while maintaining clinically relevant dosing.
The data on Xeya Modern Shatavari consistently links biomarker shifts to felt outcomes:
- Clearer thinking
- Better sleep
- More regular cycles
- Improved skin and hair quality
- Greater emotional resilience
If you’re building women’s health products for:
- Menstrual cycle regularity
- PCOS-adjacent support
- Reproductive wellness
- Perimenopause resilience
- Menopausal balance
- Hormonal rhythm and quality-of-life outcomes
Xeya Modern Shatavari offers something rare in this category: low dose, more flexibility, real clinical proof. Because hormonal health isn’t the goal. Freedom is.
References
- Kondamudi, S.; et all. CL22209, a standardized Asparagus racemosus root extract, demonstrates improved ovarian morphology, menstrual regularity, and metabolic parameters in women with polycystic ovary syndrome in a randomized, controlled trial. Food & Nutrition Research. 69.
- Yadav, P.; et al. Clinical assessment of CL22209, a standardized proprietary extract of Asparagus racemosus, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study. Functional Foods in Health and Disease. 2025; 15(7).
